174 related articles for article (PubMed ID: 25406307)
1. Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but east does not meet west.
Rossignol P; Zannad F
Circulation; 2015 Jan; 131(1):7-10. PubMed ID: 25406307
[No Abstract] [Full Text] [Related]
2. International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction.
Kristensen SL; Køber L; Jhund PS; Solomon SD; Kjekshus J; McKelvie RS; Zile MR; Granger CB; Wikstrand J; Komajda M; Carson PE; Pfeffer MA; Swedberg K; Wedel H; Yusuf S; McMurray JJ
Circulation; 2015 Jan; 131(1):43-53. PubMed ID: 25406306
[TBL] [Abstract][Full Text] [Related]
3. Age-Related Characteristics and Outcomes of Patients With Heart Failure With Preserved Ejection Fraction.
Tromp J; Shen L; Jhund PS; Anand IS; Carson PE; Desai AS; Granger CB; Komajda M; McKelvie RS; Pfeffer MA; Solomon SD; Køber L; Swedberg K; Zile MR; Pitt B; Lam CSP; McMurray JJV
J Am Coll Cardiol; 2019 Aug; 74(5):601-612. PubMed ID: 31370950
[TBL] [Abstract][Full Text] [Related]
4. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial.
Pfeffer MA; Claggett B; Assmann SF; Boineau R; Anand IS; Clausell N; Desai AS; Diaz R; Fleg JL; Gordeev I; Heitner JF; Lewis EF; O'Meara E; Rouleau JL; Probstfield JL; Shaburishvili T; Shah SJ; Solomon SD; Sweitzer NK; McKinlay SM; Pitt B
Circulation; 2015 Jan; 131(1):34-42. PubMed ID: 25406305
[TBL] [Abstract][Full Text] [Related]
5. Risk of Stroke in Chronic Heart Failure Patients Without Atrial Fibrillation: Analysis of the Controlled Rosuvastatin in Multinational Trial Heart Failure (CORONA) and the Gruppo Italiano per lo Studio della Sopravvivenza nell'Insufficienza Cardiaca-Heart Failure (GISSI-HF) Trials.
Abdul-Rahim AH; Perez AC; Fulton RL; Jhund PS; Latini R; Tognoni G; Wikstrand J; Kjekshus J; Lip GY; Maggioni AP; Tavazzi L; Lees KR; McMurray JJ; ;
Circulation; 2015 Apr; 131(17):1486-94; discussion 1494. PubMed ID: 25810334
[TBL] [Abstract][Full Text] [Related]
6. Statin therapy in patients with heart failure and preserved left ventricular function.
Roik M
Circ J; 2009 Jul; 73(7):1359; author reply 1360. PubMed ID: 19556702
[No Abstract] [Full Text] [Related]
7. [Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)].
Mareev VIu
Kardiologiia; 2008; 48(1):74-5. PubMed ID: 18261000
[No Abstract] [Full Text] [Related]
8. Prognostic Importance of Changes in Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone.
Shah AM; Claggett B; Sweitzer NK; Shah SJ; Deswal A; Anand IS; Fleg JL; Pitt B; Pfeffer MA; Solomon SD
Circ Heart Fail; 2015 Nov; 8(6):1052-8. PubMed ID: 26475142
[TBL] [Abstract][Full Text] [Related]
9. [Rosuvastatin has no effect on clinical outcomes in patients with heart failure. Results of the GISSI-HF trial].
Preorazhenskiĭ DV
Kardiologiia; 2009; 49(4):64-5. PubMed ID: 19463122
[No Abstract] [Full Text] [Related]
10. Atorvastatin, not rosuvastatin, improves cardiac function in heart failure: a meta-analysis of randomized trials.
Takagi H; Umemoto T
Int J Cardiol; 2012 Mar; 155(2):296-9. PubMed ID: 22200185
[No Abstract] [Full Text] [Related]
11. Application of the H
Myhre PL; Vaduganathan M; Claggett BL; Lam CSP; Desai AS; Anand IS; Sweitzer NK; Fang JC; O'Meara E; Shah SJ; Shah AM; Lewis EF; Rouleau J; Pitt B; Solomon SD
Eur J Heart Fail; 2019 Oct; 21(10):1288-1291. PubMed ID: 31332920
[TBL] [Abstract][Full Text] [Related]
12. Designing Future Clinical Trials in Heart Failure With Preserved Ejection Fraction: Lessons From TOPCAT.
Patel RB; Shah SJ; Fonarow GC; Butler J; Vaduganathan M
Curr Heart Fail Rep; 2017 Aug; 14(4):217-222. PubMed ID: 28647918
[TBL] [Abstract][Full Text] [Related]
13. The CHARM programme.
Gama MG; Rocha G
Lancet; 2003 Nov; 362(9396):1676; author reply 1678-9. PubMed ID: 14630454
[No Abstract] [Full Text] [Related]
14. Aldosterone Receptor Blockade in Heart Failure with Preserved Ejection Fraction.
Nair A; Deswal A
Heart Fail Clin; 2018 Oct; 14(4):525-535. PubMed ID: 30266361
[TBL] [Abstract][Full Text] [Related]
15. What have we learned about patients with heart failure and preserved ejection fraction from DIG-PEF, CHARM-preserved, and I-PRESERVE?
Campbell RT; Jhund PS; Castagno D; Hawkins NM; Petrie MC; McMurray JJ
J Am Coll Cardiol; 2012 Dec; 60(23):2349-56. PubMed ID: 23141494
[TBL] [Abstract][Full Text] [Related]
16. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
[TBL] [Abstract][Full Text] [Related]
17. Clinical Question: In congestive heart failure patients with preserved ejection fraction, does spironolactone improve cardiac outcomes?
Onarecker C
J Okla State Med Assoc; 2016 Sep; 109(9):437-8. PubMed ID: 29261854
[TBL] [Abstract][Full Text] [Related]
18. Heart failure patients with preserved left ventricular ejection fraction did not benefit from additional ARB therapy.
Cardiovasc J Afr; 2008; 19(6):337-8, discussion 339. PubMed ID: 19104736
[No Abstract] [Full Text] [Related]
19. Impact of Spironolactone on Longitudinal Changes in Health-Related Quality of Life in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial.
Lewis EF; Kim HY; Claggett B; Spertus J; Heitner JF; Assmann SF; Kenwood CT; Solomon SD; Desai AS; Fang JC; McKinlay SA; Pitt BA; Pfeffer MA;
Circ Heart Fail; 2016 Mar; 9(3):e001937. PubMed ID: 26962133
[TBL] [Abstract][Full Text] [Related]
20. Effect of Mineralocorticoid Receptor Antagonists in Individuals With Heart Failure With Preserved Ejection Fraction: A Systematic Review.
Fernandes BP; Conceição LSR; Martins-Filho PRS; de Santana Motta DRM; Carvalho VO
J Card Fail; 2018 Sep; 24(9):618-621. PubMed ID: 30194985
[No Abstract] [Full Text] [Related]
[Next] [New Search]
